DB
ALGS icon

Dmitry Balyasny’s Aligos Therapeutics ALGS Stock Holding History

Dmitry Balyasny’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-480
Closed -$13K – 2741
2022
Q3 		$13K Buy
+480
New +$15.9K ﹤0.01% 2623

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dmitry Balyasny's ALGS Position: Q4 2022 in Review

Dmitry Balyasny sold out of Aligos Therapeutics (ALGS) in Q4 2022, closing a stake of 480 shares — an estimated $13K sold.

Dmitry Balyasny first reported a position in ALGS in Q3 2022 and held it in 1 quarter. The position peaked at $13K in Q3 2022. 38 funds tracked by Wall St. Rank hold ALGS as of Q4 2022.

  • Dmitry Balyasny reported no remaining Aligos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Dmitry Balyasny sold 480 Aligos Therapeutics shares in Q4 2022, an estimated $13K.
  • Dmitry Balyasny first reported a position in Aligos Therapeutics in Q3 2022 and held it in 1 quarter.
  • Dmitry Balyasny's Aligos Therapeutics position peaked at $13K in Q3 2022.
  • 38 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.